Gene Therapy Shows High Success Rate for Children with ADA-SCID
An experimental gene therapy has successfully treated 48 of 50 children with ADA-SCID, restoring immune function in the majority. The therapy, involving lentiviral vectors, shows promising long-term results with no serious complications reported.
An international trial of a lentiviral gene therapy has shown success in treating children with adenosine deaminase deficiency severe combined immunodeficiency (ADA-SCID), a rare genetic disorder that leaves individuals without a functioning immune system. Conducted by researchers from UCLA and Great Ormond Street Hospital (GOSH), the study involved 50 children, and treatment successfully restored immune function in 48 of them. All patients have survived and are reported to be well after two to three years of follow-up, marking a significant advancement in the treatment of this life-threatening condition.
ADA-SCID is caused by mutations in the ADA gene, which is essential for producing the enzyme adenosine deaminase, crucial for a healthy immune response. Without treatment, children with ADA-SCID are at high risk for life-threatening infections, often leading to fatal outcomes within the first two years of life. The investigational gene therapy involves collecting blood-forming stem cells from the child, introducing a corrected copy of the ADA gene using a modified lentivirus, and returning the treated cells to the child’s body. This approach aims to provide a lifelong solution by enabling the production of healthy immune cells.
The study, published in the New England Journal of Medicine, details the outcomes of children treated in clinical trials at GOSH, UCLA Mattel Children's Hospital, and the National Institutes of Health between 2012 and 2017. Co-lead authors Dr. Donald Kohn and Dr. Claire Booth noted that all participants are alive and well, with over 95% experiencing a correction of their immune system problems. Importantly, no serious complications or treatment-limiting events were reported, indicating the therapy's safety and efficacy.
In addition to the promising success rates, the gene therapy represents a potential shift in treatment paradigms for ADA-SCID and similar genetic disorders. Traditionally, patients required frequent injections of the ADA enzyme or bone marrow transplants, which can be challenging due to donor availability and associated risks. This one-time gene therapy could eliminate the need for these burdensome treatments, providing a more accessible and effective option for families worldwide, particularly in regions where standard therapies are not readily available.
Looking to the future, the research team emphasizes the need for continued development and potential approval of this innovative therapy. The collaboration among leading researchers in gene therapy has paved the way for advancements that could benefit not only ADA-SCID patients but also those with various genetic conditions. By harnessing the potential of lentiviral vectors, the team aims to enhance the safety and efficacy of gene therapies, ultimately improving the quality of life for children suffering from genetic disorders. The success of this trial marks a hopeful milestone in the field of gene therapy, reinforcing the potential for transformative treatments in modern medicine.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Daniel writes about people solving big problems in small, human ways.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
